Begin main content

Call for Patient Input: Xarelto

April 25, 2018
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website. Xarelto Brand name Generic name Manufacturer I...

New at CADTH — April 2018

April 23, 2018
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

2018 Call for Nominations

April 19, 2018
CADTH has released a Call for Nominations to attract qualified candidates to join our advisory and expert committees. We are seeking a number of new members, including patient, clinician, and public members who have a range of education, experience, and skill sets from across the country. This is an exciting opportunity to become involved in the...

CADTH to Evaluate CAR T-Cell Therapies

April 17, 2018
Since the FDA approved the first gene therapy in 2017, Canadian patients, health care providers, and decision-makers have been anticipating the arrival of chimeric antigen receptor (CAR) T-cell therapies in Canada. During this time, CADTH has been considering how to effectively and rigorously assess the clinical effectiveness and value that thes...

CADTH Recognizes “Rising Star” Dr. Michelle Mujoomdar

April 17, 2018
Halifax, NS (April 17, 2018) — CADTH is pleased to announce that Dr. Michelle Mujoomdar is the 2018 recipient of the Dr. Maurice McGregor Award recognizing rising stars in the field of health technology assessment early in their careers. She will accept the award today at a luncheon in Halifax in front of more than 700 people attending the 2018 ...